WO2024194851 - BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF
National phase entry:
Publication Number
WO/2024/194851
Publication Date
26.09.2024
International Application No.
PCT/IB2024/052794
International Filing Date
22.03.2024
Title **
[English]
BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF
[French]
CONJUGUÉ BIOACTIF, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
Applicants **
BEONE MEDICINES I GMBH
BEONE GUANGZHOU BIOLOGICS MANUFACTURING CO., LTD.
Inventors
TSAI, Charng-sheng
TSAI, Mei-Hsuan
LI, Bing
WU, Liming
Priority Data
PCT/CN2023/083522
23.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5067 | |
| EPO | Filing, Examination, Granting | 81383 | |
| Japan | Filing, Examination, Granting | 4501 | |
| South Korea | Filing, Examination, Granting | 6850 | |
| USA | Filing, Examination, Granting | 21190 |
Total:
118,991
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides antibody drug conjugate platforms comprising a conjugator assembly component, and antibody drug conjugates comprising platform-derived linker-payloads and antibodies or antigen-binding fragments thereof. In some embodiments, an antibody drug conjugate is of the following formula (I) or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, wherein values for the variables (e.g., BA, U, V, A, a', W, w', Y, y', PA, x) are as described herein.[French]
La présente invention concerne des plateformes conjuguées anticorps-médicament comprenant un composant d'ensemble conjugué, et des conjugués anticorps-médicament comprenant des charges utiles de lieur dérivées de plateforme et des anticorps ou des fragments de liaison à l'antigène de ceux-ci. Dans certains modes de réalisation, un conjugué anticorps-médicament est de formule (I) suivante ou un sel, un tautomère, un solvate ou un stéréoisomère pharmaceutiquement acceptable de celui-ci, des valeurs pour les variables (par exemple, BA, U, V, A, a', W, w', Y, y', PA, x) étant telles que décrites dans la description.